Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C

Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, No 2 Yuh-Der Road, Taichung, 40402, Taiwan. .
BMC Gastroenterology (Impact Factor: 2.37). 08/2012; 12(1):105. DOI: 10.1186/1471-230X-12-105
Source: PubMed

ABSTRACT Previous research has shown variation in the effects of patient factors, including hepatic necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study attempts to identify explanatory factors for LSM in patients with chronic hepatitis C (CHC) using acoustic radiation force impulse (ARFI) technology.
A cohort of 127 Taiwanese patients with CHC underwent ARFI LSM and immediate percutaneous liver biopsy. This study compares the concurrent diagnostic performances of LSM and FibroTest using receiver operating characteristic (ROC) curves. Three multiple linear regression models were used to evaluate the significance of concurrent patient factors in explaining LSM.
To classify METAVIR fibrosis (F) stages, the areas under ROC curves (AUCs) were ARFI LSM, 0.847 (95% confidence interval (CI), 0.779-0.914) and FibroTest, 0.823 (95% CI, 0.748-0.898), for F1 versus F2-4; ARFI LSM, 0.902 (95% CI, 0.835-0.970) and FibroTest, 0.812 (95% CI, 0.735-0.888), for F1-2 versus F3-4; ARFI LSM, 0.831 (95% CI, 0.723-0.939) and FibroTest, 0.757 (95% CI, 0.648-0.865), for F1-3 versus F4. After adjusting for other demographic and biological covariates, biochemical and histological necroinflammatory factors consistently explained LSM. Factors included serum alanine aminotransferase (ALT)/upper limit of normal (ULN) categories (model R2 = 0.661, adjusted R2 = 0.629), ActiTest A scores (R2 = 0.662, adjusted R2 = 0.636), and METAVIR activity (A) grades (R2 = 0.651, adjusted R2 = 0.620). METAVIR F stages, body mass index, and platelet count were also independently associated with LSM. Necroinflammatory degrees, including ALT/ULN, ActiTest A scores, and METAVIR A grades, explained the false positivity of liver fibrosis staging using ARFI LSM.
The degree of hepatic necroinflammatory activity independently and significantly exaggerated liver fibrosis evaluation using ARFI LSM. However, comparisons with concurrent FibroTest indicate that ARFI LSM may be a promising alternative, or adjunctive single indicator, for liver fibrosis evaluation in patients with CHC.

Download full-text


Available from: Cheng-Yuan Peng, Sep 29, 2015
19 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: An accurate assessment of the degree of fibrosis or presence of cirrhosis is critical both for the appropriate management of, and to provide prognosis for, patients with chronic hepatitis C infection. In the new era of direct acting antivirals, large numbers of patients may enter therapy, and although liver biopsy remains the gold standard, it is not practical in all settings. In recent years, a variety of noninvasive methods have been developed that may obviate the need for liver biopsy in most settings. Indirect laboratory formulas, tests, panels of biomarkers and imaging modalities may accurately stage the degree of fibrosis in hepatitis C monoinfection, hepatitis C/HIV coinfection, and post-transplant recurrent hepatitis C.
    Current Gastroenterology Reports 02/2013; 15(2):307. DOI:10.1007/s11894-012-0307-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Acoustic Radiation Force Impulse Imaging (ARFI) is an innovative elastography for staging of liver fibrosis. We evaluated the diagnostic accuracy of different probes to perform ARFI at different insertion depths. Methods: In a prospective study, 89 chronic HCV infected patients underwent ARFI elastography using both available probes (c-ARFI: C4-1-MHz; l-ARFI: L9-4 MHz) in comparison to Fibroscan(®). Variability of ARFI elastography at different insertion depths was systematically evaluated in 39 patients (44%). According to Fibroscan(®) elastography, 32 patients (36%) presented with liver cirrhosis, 23 patients (26%) had significant fibrosis and 34 patients (38%) had no significant fibrosis. Results: Mean propagation velocity with c-ARFI was 1.70±0.67m/s and 1.91±0.87m/s with l-ARFI. Results of both probes were correlated to each other (p<0.001; r=0.70) and to Fibroscan(®) (p<0.001, r=0.82 and 0.84, respectively). In patients with significant fibrosis or with cirrhosis, mean values by l-ARFI were significantly higher than by c-ARFI (p<0.001). For detection of liver cirrhosis, AUROC was 0.97 for c-ARFI (cut-off level 1.72m/s) and 0.90 for l-ARFI (cut-off 2.04m/s). Correlation coefficients of c-ARFI with Fibroscan(®) were highest at an insertion depth of 5-6cm (r=0.882 and 0.864, respectively, p<0.001) and at 3-4cm for l-ARFI (r=0.850 and 0.838, respectively, p<0.001). Conclusions: ARFI elastography with the linear and with the convex probes showed comparable validity and accuracy in the estimation of liver stiffness. The linear probe gave higher ARFI values. The most accurate insertion depth was 5-6cm for c-ARFI and 3-4cm for l-ARFI indicating that measurements should not be performed close to the liver capsule.
    European journal of radiology 03/2013; 82(8). DOI:10.1016/j.ejrad.2013.02.011 · 2.37 Impact Factor
  • Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine 05/2013; 32(5):886-8. DOI:10.7863/ultra.32.5.886 · 1.54 Impact Factor
Show more